Subscribe
rawpixel-com-shutterstock-com
Rawpixel.com / Shutterstock.com
29 January 2016Americas

You’re out of time: PTAB rules IPR petition is time-barred

The Patent Trial and Appeal Board (PTAB) has rejected generics company Lannett Holdings’s petition for an inter partes review (IPR) because it was filed one day too late.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AstraZeneca’s Zomig patents upheld in precedential ruling
2 July 2018   The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
AstraZeneca’s Zomig patents upheld in precedential ruling
2 July 2018   The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.

More on this story

Americas
AstraZeneca’s Zomig patents upheld in precedential ruling
2 July 2018   The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent